J&J withdrawing ceftobiprole in Switzerland

Basilea Pharmaceutica AG (SIX:BSLN) said former partner Johnson & Johnson (NYSE:JNJ) is discontinuing sales of Zevtera ceftobiprole for complicated skin and soft tissue infections (cSSTI) in Switzerland as of Sept. 17. Basilea said the decision came in response to recent "unfavorable" regulatory actions on applications for ceftobiprole in the U.S. and Europe. Basilea also said J&J is submitting requests for the withdrawal of marketing authorization in the three remaining countries where ceftobiprole is approved: Russia, Ukraine and Azerbaijan. J&J discontinued sales of ceftobiprole in Canada in April. ...